PROCESS DEVELOPMENT OF TELACEBEC FOR TUBERCULOSIS

NIH RePORTER · NIH · N01 · $605,287 · view on reporter.nih.gov ↗

Abstract

The overall objective of this project is for the contractor to support the chemistry, manufacturing, and controls (CMC) development of Telacebec (Q203), to treat Tuberculosis.

Key facts

NIH application ID: 11219854
Project number: 75N95024D00012-0-759502400002-1
Recipient: MIDWEST RESEARCH INSTITUTE
Principal Investigator: DESMOND SLADE
Activity code: N01
Funding institute: NIH
Fiscal year: 2024
Award amount: $605,287
Award type: —
Project period: 2024-09-30 → 2026-09-29